An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors

NCT00030043 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2015-03-25

No results posted yet for this study

Summary

This is a study to gather some information on the safety and efficacy of the penetrating auditory brainstem implant (PABI) in patients with neurofibromatosis type 2.

Conditions

  • Neurofibromatosis 2

Interventions

DEVICE

Penetrating auditory brainstem implant

Sponsors & Collaborators

  • FDA Office of Orphan Products Development

    lead FED

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-09-30
Completion
2003-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00030043 on ClinicalTrials.gov